Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids(Dana-Farber Cancer Institute), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Monali Desai(AbbVie (United States)), Lori A. Gressick(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Thomas J. Kipps(University of California San Diego), John M. Pagel(University of Washington), Ahmed Hamed Salem(Ain Shams University), Jeremy A. Ross(AbbVie (United States)), Rod Humerickhouse(Abbott Fund), Franklin Peale(Unknown), Brad S. Kahl(UW Health University Hospital), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Su Young Kim(Yonsei University), Gary Gordon, Soham D. Puvvada(University of Arizona), Maria Verdugo(AbbVie (United States)), Martin Dunbar(AbbVie (United States))
Cited by 752
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k